|Last Update: 05/24/13 - 4:00 PM EDT|
|YTD Performance: 15.79%|
|Previous Close: $29.11|
|52 Week Range: $21.40 - $31.15|
|Oustanding Shares: 7,093,223,330|
|Market Cap: 206,483,731,136|
|Qtr (06/13)||Qtr (09/13)||FY (12/13)||FY (12/14)|
|Number of Analysts||5||5||8||7|
|Growth Rate (Year over Year)||-9.03%||3.02%||1.43%||5.54%|
Here are seven reasons why.
A move below 1575 on the S&P 500 would be a signal to go short.
Focusing on near-term drug stock earnings is the wrong move.
PFE earnings estimates were reduced to reflect the impact of FX, said UBS.
Pfizer Annual Shareholder Meeting - 8:30AM
It’s the only thing that explains today’s action.
These name capitalize on the trend of spending on our pets, which has become recession proof.
Jim Cramer looks at why he is highlighting pharma along with growth biotech, with Nicole Urken, Mad Money Research Associate.
The recent stock pullback is making dividend yields for Procter & Gamble, Pfizer and Bank of America, more attractive. Portfolio Manager David Peltier expects to see more payout increases this spring.